Literature DB >> 29173262

Users' guide to the surgical literature: how to assess a noninferiority trial.

Achilleas Thoma1, Forough Farrokhyar1, Daniel Waltho1, Luis H Braga, Sheila Sprague1, Charlie H Goldsmith1.   

Abstract

SUMMARY: A well-planned randomized controlled trial (RCT) is the most optimal study design to determine if a novel surgical intervention is any different than a prevailing one. Traditionally, when we want to show that a new surgical intervention is superior to a standard one, we analyze data from an RCT to see if the null hypothesis of "no difference" can be rejected (i.e., the 2 surgical interventions have the same effect). A noninferiority RCT design seeks to determine whether a new intervention is not worse than a prevailing (standard) one within an acceptable margin of risk or benefit, referred to as the "noninferiority margin." In the last decade, we have observed an increase in the publication of noninferiority RCTs. This article explores this type of study design and discusses the tools that can be used to appraise such a study.

Mesh:

Year:  2017        PMID: 29173262      PMCID: PMC5726973          DOI: 10.1503/cjs.000317

Source DB:  PubMed          Journal:  Can J Surg        ISSN: 0008-428X            Impact factor:   2.089


  23 in total

1.  Users' guide to the surgical literature. How to assess a randomized controlled trial in surgery.

Authors:  Achilleas Thoma; Forough Farrokhyar; Mohit Bhandari; Ved Tandan
Journal:  Can J Surg       Date:  2004-06       Impact factor: 2.089

2.  Hypothermic continuous machine perfusion enables preservation of energy charge and functional recovery of heart grafts in an ex vivo model of donation following circulatory death.

Authors:  Olivier Van Caenegem; Christophe Beauloye; Luc Bertrand; Sandrine Horman; Sophie Lepropre; Grégory Sparavier; Jonathan Vercruysse; Noëlla Bethuyne; Alain J Poncelet; Pierre Gianello; Peter Demuylder; Eric Legrand; Gwen Beaurin; Françoise Bontemps; Luc M Jacquet; Jean-Louis Vanoverschelde
Journal:  Eur J Cardiothorac Surg       Date:  2015-11-24       Impact factor: 4.191

Review 3.  Choice of delta: requirements and reality--results of a systematic review.

Authors:  S Lange; G Freitag
Journal:  Biom J       Date:  2005-02       Impact factor: 2.207

4.  Ex vivo reconditioning of marginal donor lungs injured by acid aspiration.

Authors:  Ilhan Inci; Luca Ampollini; Stephan Arni; Wolfgang Jungraithmayr; Demet Inci; Sven Hillinger; Boris Leskosek; Peter Vogt; Walter Weder
Journal:  J Heart Lung Transplant       Date:  2008-10-01       Impact factor: 10.247

Review 5.  Preservation of the donor heart: from basic science to clinical studies.

Authors:  Sarkis M Minasian; Michael M Galagudza; Yuri V Dmitriev; Andrey A Karpov; Timur D Vlasov
Journal:  Interact Cardiovasc Thorac Surg       Date:  2014-12-23

6.  The well-built clinical question: a key to evidence-based decisions.

Authors:  W S Richardson; M C Wilson; J Nishikawa; R S Hayward
Journal:  ACP J Club       Date:  1995 Nov-Dec

7.  Ex-vivo perfusion of donor hearts for human heart transplantation (PROCEED II): a prospective, open-label, multicentre, randomised non-inferiority trial.

Authors:  Abbas Ardehali; Fardad Esmailian; Mario Deng; Edward Soltesz; Eileen Hsich; Yoshifumi Naka; Donna Mancini; Margarita Camacho; Mark Zucker; Pascal Leprince; Robert Padera; Jon Kobashigawa
Journal:  Lancet       Date:  2015-04-14       Impact factor: 79.321

8.  Normothermic ex vivo allograft blood perfusion in clinical heart transplantation.

Authors:  Michael M Koerner; Ali Ghodsizad; Uwe Schulz; Aly El Banayosy; Reiner Koerfer; Gero Tenderich
Journal:  Heart Surg Forum       Date:  2014-06       Impact factor: 0.676

9.  Removal of blood group A/B antigen in organs by ex vivo and in vivo administration of endo-beta-galactosidase (ABase) for ABO-incompatible transplantation.

Authors:  Takaaki Kobayashi; Dage Liu; Haruko Ogawa; Yuko Miwa; Takaharu Nagasaka; Shoichi Maruyama; Yu-Teh Li; Akira Onishi; Masaki Iwamoto; Takafumi Kuzuya; Kenji Kadomatsu; Kazuharu Uchida; Akimasa Nakao
Journal:  Transpl Immunol       Date:  2008-10-07       Impact factor: 1.708

10.  Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement.

Authors:  Gilda Piaggio; Diana R Elbourne; Stuart J Pocock; Stephen J W Evans; Douglas G Altman
Journal:  JAMA       Date:  2012-12-26       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.